反応式
C[O:2][C:3]1[CH:20]=[C:19]([C:21]([OH:23])=O)[CH:18]=[C:17]2[C:4]=1[C@H:5]1[C@H:14]([CH2:15][S:16]2(=[O:25])=[O:24])[C@:13]2([CH3:26])[C@H:8]([C:9]([CH3:28])([CH3:27])[CH2:10][CH2:11][CH2:12]2)[CH2:7][CH2:6]1.CN(C(ON1N=N[C:39]2[CH:40]=[CH:41][CH:42]=[N:43][C:38]1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.[CH3:53]N1CCOCC1.N1([C:66]([O:68][CH3:69])=[O:67])CCCCC1>C1COCC1.CN(C=O)C>[OH:2][C:3]1[CH:20]=[C:19]([C:21]([N:43]2[CH2:38][CH2:39][CH:40]([C:66]([O:68][CH3:69])=[O:67])[CH2:41][CH2:42]2)=[O:23])[CH:18]=[C:17]2[C:4]=1[C@@:5]1([CH3:53])[C@H:14]([CH2:15][S:16]2(=[O:24])=[O:25])[C@:13]2([CH3:26])[C@H:8]([C:9]([CH3:27])([CH3:28])[CH2:10][CH2:11][CH2:12]2)[CH2:7][CH2:6]1参加物
反応物 4
生成物 1
試薬・触媒・溶媒 2
実験手順
A mixture of (1R,10S,11S,16S)-3-methoxy-11,15,15-trimethyl-8,8-dioxo-8λ6-thiatetracyclo[8.8.0.02,7.011,16]octadeca-2,4,6-triene-5-carboxylic acid (61) (0.20 g, 0.49 mmol), HATU (0.37 g, 0.98 mmol), N-methylmorpholine (0.10 mL, 1.5 mmol) and methyl piperidinecarboxylate (0.2 mL, 2 mmol) in THF (10 mL) and DMF (2.0 mL) was stirred at room temperature for 18 h. The THF was evaporated under reduced pressure, the residue was quenched with water and the resulting solid was collected by filtration. The crude product was purified by flash column chromatography on silica gel (CH2Cl2/MeOH, 20:1) to give methyl 1-{[(1R,10R,11S,16S)-3-hydroxy-1,11,15,15-tetramethyl-8,8-dioxo-8λ6-thiatetracyclo[8.8.0.02,7.011,16]octadeca-2,4,6-trien-5-yl]carbonyl}piperidine-4-carboxylate (97) (0.10 g, 37%) as a white solid.
後処理
- customThe THF was evaporated under reduced pressure
- customthe residue was quenched with water
- filtrationthe resulting solid was collected by filtration
- customThe crude product was purified by flash column chromatography on silica gel (CH2Cl2/MeOH, 20:1)
出典と根拠
- ORDレコード
- ord-49e9c75e29274e50bf65197bbbccf1d0
- 出典データセット
- uspto-grants-2012_01
- 特許番号
- US08101605B2
関連ノート
読み込み中…